Showing 61-70 of 7665 results for "".
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in the global gross domestic product growth during 20…
- Federated Learning Comparable to Traditional Learning Methods for AI-based Melanoma Diagnosishttps://practicaldermatology.com/news/federated-learning-comparable-to-traditional-learning-methods-for-ai-based-melanoma-diagnosis/2462238/A decentralized federated learning approach was comparable in diagnostic performance to traditional centralized and ensemble learning methods in AI-based melanoma diagnosis, new research suggests. Study authors conducted a multicentric, single-arm diagnostic study conducted across six German unive…
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clinical response at 48 weeks. “Hidradenitis suppurativa is a chronic and painful in…
- NPF Welcomes Four New Board Membershttps://practicaldermatology.com/news/npf-welcomes-four-new-board-members/2461907/The National Psoriasis Foundation (NPF) is adding four new members to the NPF Board of Directors. Andrew Blauvelt, MD, MBA, Valerie Harrison, PhD, Brian Janssen, and Diana Sandler, MD. will serve two-year terms effective July 1, 2023. Dr. Blauvelt will also serve as the Chair of the NPF Medical B…
- DefenAge Scores Defensin Master Anti-Aging Patenthttps://practicaldermatology.com/news/defenage-scores-defensin-master-anti-aging-patent/2461443/DefenAge Skincare received Defensin Master Anti-Aging Patent from the US Patent Office (Patent #11,491,096). The new patent recognizes DefenAge's ground-breaking cell stimulating compositions and methods to create fresh, new skin. This patent concludes the international family of DefenAge's patent…
- Crown’s Patented Xycrobe Technology Supports a Healthy Skin Microbiomehttps://practicaldermatology.com/news/crowns-patented-xycrobe-technology-supports-a-healthy-skin-microbiome/2461440/Crown Aesthetics’ BIOJUVE regimen, which incorporates the patented Xycrobe technology, supports a healthy skin environment, promotes increased skin hydration, decreases redness, regulates sebum production and reduces the appearance of signs of aging such as fine lines and photodamage, according to …
- NPF COVID-19 Task Force: Masks, Social Distancing Still Important for Many Vaccinated Psoriasis Patientshttps://practicaldermatology.com/news/npf-covid-19-task-force-masks-social-distancing-still-important-for-many-vaccinated-psoriasis-patients/2460818/In mid-May 2021, the Centers for Disease Control and Prevention (CDC) released new public health recommendations for fully vaccinated individuals. These guidelines stated that fully vaccinated people no longer need to wear a mask or physically distance in any setting, except where required by law, …
- FDA Accepts Amgen's sNDA for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/fda-accepts-amgens-snda-for-otezla-in-mild-to-moderate-pso/2460796/FDA has accepted for review the supplemental New Drug Application (sNDA) for Amgen's Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a PDUFA action date of December 19, 2021. The sNDA, …
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021. In ADVANCE, oral Otez…
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment s…